

CONTENTS

Preface	xi
Acknowledgments	xiv
Biographies	xv
Contributors	xix
REGULATORY ISSUES, EPIDEMIOLOGY, AND EMERGING VIRUSES	1
Current issues in the regulation and approval of antiviral drugs for hepatitis	3
<i>Barbara A Styrt, Russell Fleischer, Teresa Wu, and Heidi M Jolson</i>	
Molecular and serum epidemiology of HBV and HCV infection and the impact of antiviral agents in China	15
<i>Xuefeng Liu and Raymond F Schinazi</i>	
New viruses and their relationship to hepatitis	35
<i>Harvey J Alter</i>	
IMMUNOLOGY AND VACCINES	47
Virus-specific CD8 ⁺ cell immune responses in acute and chronic hepatitis B virus infection	49
<i>George JM Webster and Geoffrey M Dusheiko</i>	
Cell-mediated immunity and the outcome of HCV infection in chimpanzees	59
<i>Chris M Walker</i>	
Adoptive immune transfer as a therapeutic approach for persistent hepatitis B virus infection	71
<i>Daniel Shouval</i>	

Perspectives in HCV vaccine development	77
<i>Erik Depla</i>	
VIRAL HEPATITIS B AND C INFECTIONS IN CHILDREN	87
Maternal/fetal/pediatric HBV and HCV infections	89
<i>Richard A Schreiber</i>	
Effects of interferon treatment in children with post-transfusional chronic hepatitis B	97
<i>Maria Pop, M Serban, L Cionca, R Costa, and C Jinca</i>	
GENETICS, PATHOLOGY AND VIRAL DIAGNOSIS	107
Effects of genotypic variations on hepatitis C virus nonstructural protein 5B structure and activity	109
<i>Zhi Hong, Eric B Ferrari, Angela Skelton, Jacquelyn Wright-Minogue, Weidong Zhong and Charles Lesburg</i>	
Compartmentalization of hepatitis C viral quasispecies	123
<i>Xiaofeng Fan, Andre Castro Lyra and Adrian M DiBisceglie</i>	
<i>In situ</i> localization of PCR-amplified hepatitis C virus RNA on human erythrocytes	131
<i>Susan Simon, Gabor Lotz, Fritz Kury, Brigit Reipert, Alexander Steinkasserer, Martha M Eibl and Zsuzsa Schaff</i>	
Nucleic acid-based antiviral approaches to HBV	139
<i>HC Spangenberg and JR Wands</i>	
<i>In vitro</i> phenotype of HBV variants in patients with fulminant hepatitis B	157
<i>Martina Sterneck and T Kalinina</i>	
Evaluation of three commercially available HBV viral load assays: dynamic range, precision, and clinical utility	165
<i>Andrea Snow, Florence Myrick, Charles Wakeford and Bruce McCreedy</i>	

CELL SYSTEMS AND ANIMAL MODELS	173
Cell lines that allow regulated expression of HCV proteins: principles and applications	175
<i>Darius Moradpour, Markus H Heim, Andreas Cerny, Charles M Rice and Hubert E Blum</i>	
Novel hepatitis C virus-positive cell line derived from a chimpanzee with chronic HCV infection	187
<i>Borislava G Pavlova, Zsuzsa Schaff and Gerald Eder</i>	
A transgenic mouse lineage useful for testing antivirals targeting hepatitis B virus	197
<i>PL Marion, FH Salazar, K Liittschwager, BB Bordier, C Seeger, MA Winters, AD Cooper and JM Cullen</i>	
Evaluation of therapies for hepatitis B virus in the HBV transgenic SCID mouse model	211
<i>Milind Kamkolkar, Marcia M Clayton, Shu Min Zhang, Paul Black, Raymond F Schinazi and Mark A Feitelson</i>	
DRUG DISCOVERY AND DEVELOPMENT: NOVEL THERAPEUTICS FOR HEPATITIS B AND C	223
Novel approaches in the management of chronic HBV infection	225
<i>Angeline Bartholomeusz, Phillip Furman and Stephen Locarnini</i>	
Antiviral β -L-nucleosides specific for hepatitis B virus infection	245
<i>Martin L Bryant, Edward G Bridges, Laurent Placidi, Abdesslem Faraj, Anna-Giulia Loi, Claire Pierra, David Dukhan, Gilles Gosselin, Jean-Louis Imbach, Brenda Hernandez, Amy Juodawlkis, Bud Tennant, Brent Korba, Paul Cote, Erika Cretton-Scott, Raymond F Schinazi, Maureen Myers and Jean-Pierre Sommadossi</i>	
Toxicological study of the anti-HBV agent β -L-thymidine	263
<i>Edward G Bridges, Martin L Bryant, Laurent Placidi, Abdesslem Faraj, Anna-Giulia Loi, Claire Pierra, David Dukhan, Gilles Gosselin, Jean-Louis Imbach, Brenda Hernandez, Amy Juodawlkis, Bud Tennant, Erika Cretton-Scott and Jean-Pierre Sommadossi</i>	

Pharmacokinetics of β -L-thymidine and β -L-2'-deoxycytidine in woodchucks and monkeys	271
<i>Erika Cretton-Scott, Edward G Bridges, Bud C Tennant, Amy Juodawlakis, Gilles Gosselin, Jean-Louis Imbach, Claire Pierra, David Dukhan, Martin Bryant and Jean-Pierre Sommadossi</i>	
Clevudine: A novel 1- β -L nucleoside analogue in clinical development for the treatment of HBV infection	281
<i>George R Painter, Lawrence C Trost, M Robert Blum, George M Szczech, and Phillip A Furman</i>	
Glucosidase/protein folding inhibitors as possible mutation-proof, anti-hepatitis B & C agents	301
<i>Timothy M Block, Robert Jordan, Xuanyong Lu, Anand Mehta, Donald Picker, Gary Jacob, Baruch S Blumberg and Raymond A Dwek</i>	
Nuclease resistant ribozymes directed against hepatitis C virus RNA plus and minus strand inhibit viral replication of a HCV/poliovirus chimera	315
<i>LM Blatt, KL Jensen, L Bellon, SF Jamison, PA Pavco, and DG Macejak</i>	
Mechanism of laser therapy of viral hepatitis	325
<i>Victor Ovsianikov</i>	
DRUG DISCOVERY AND DEVELOPMENT: RESISTANCE AND THERAPEUTIC STRATEGIES IN HUMANS	
333	
Nomenclature for antiviral resistant human hepatitis B virus mutations in the polymerase region	335
<i>Lieven J Stuyver, Stephen A Locarnini, Anna Lok, Douglas D Richman, William F Carman, Jules L Dienstag, Raymond F Schinazi, and the HEP DART International Committee</i>	
Complex genotypic changes during failure of HBV nucleoside analogue therapy . .	353
<i>Deenan Pillay, David Mutimer, Nigel Burroughs, David Cooper and Pat Cane</i>	
Lamivudine for chronic hepatitis B: Efficacy, safety, resistance, and current treatment issues	365
<i>Nathaniel A Brown</i>	

Clinical experience and follow-up with lamivudine in the Asian population 383
Ching-Lung Lai, Man-Fung Yuen

Impaired response to 5 mU/day interferon treatment in
 African-Americans with chronic hepatitis C 391
Alessandra Colantoni, Nicola De Maria and David H Van Thiel

Novel combined approaches to hepatitis C therapies 399
Markus Cornberg and Michael P Manns

Consensus + pegylated interferon 413
Jenny Heathcote

Impact of interferon alpha-2b and of combination with ribavirin
 on progression of liver fibrosis in patients with chronic hepatitis C 425
*Thierry Poynard, John McHutchison, Gary L Davis,
 Rafael Esteban-Mur, Zachary Goodman, Pierre Bedossa and
 Janice Albrecht for the FIBROVIRC Project Group*

Decorin expression in chronic hepatitis C; effect of interferon alpha treatment 441
Ilona Kovalszky, Katalin Jármay, József Dudás and Zsuzsa Schaff

Preclinical and clinical development of the anti-HIV,
 anti-HBV oxathiolane nucleoside analog emtricitabine 451
*George R. Painter, Laurence T. Rimsky, Phillip A. Furman, Dennis C. Liotta,
 Raymond F. Schinazi and Joseph B. Quinn*

CD81 receptor expression in human cells: Implications for HCV therapeutics 485
*Phillip M. Tharnish, Amy S. Juodawlakis,
 Craig L. Hill and Raymond F. Schinazi*

**PREVENTION AND TREATMENT OPTIONS
 FOR HEPATOCELLULAR CARCINOMA 493**

Resolution of hepatic fibrosis as a consequence of
 interferon therapy for hepatitis C 495
Yasushi Shiratori, Haruhiko Yoshida and Masao Omata

Symptomatic therapies for prevention of hepatocellular carcinoma developing in chronic hepatitis C	515
<i>Hiroshi Yotsuyanagi, Yuzo Miyakawa and Shiro Iino</i>	
Mutations of the core gene sequence of HCV from patients with hepatocellular carcinoma in China	531
<i>Toshihiro Omoya, Ichiro Shimizu, Chiyo Horie, Takahiro Horie, Deng-Fu Yao, Mina Itonaga, Yoshihiro Okamura, Hirohito Honda and Susumu Ito</i>	
Characterization of hepatitis B virus X variants that are integrated and expressed in human hepatocellular carcinomas	547
<i>Wei Ning Chen and Chong Jin Oon</i>	
Subject index	557
Author index	567